5304-59-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-chlorophenyl)biguanide is used as an inhibitor for dihydrofolate reductase (DHFR) due to its significant inhibitory effect on the enzyme. This makes it a promising candidate for the development of new drugs targeting diseases and conditions related to the overactivity or abnormal functioning of DHFR.

InChI:InChI=1/C8H10ClN5/c9-5-1-3-6(4-2-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)

Upstream product

• 102-02-3 1-phenylbiguanide 
• 106-47-8 4-chloro-aniline 
• 127099-85-8 N-Cyanoguanidine 
• 20265-96-7 p-chloroaniline hydrochloride 

Downstream Products

• 102467-63-0 1-(6-bromo-quinazolin-4-yl)-5-(4-chloro-phenyl)-biguanide 
• 16120-20-0 4,6-Diamino-1-(4-chloro-phenyl)-1H-[1,3,5]triazin-2-one 
• 645-18-1 N-(4-chloro-phenyl)-6-methyl-[1,3,5]triazine-2,4-diamine 
• 41283-00-5 N²-(4-chlorophenyl)-6-phenyl-1,3,5-triazine-2,4-diamine 
• 39435-07-9 trans-{Rh(N-p-chlorophenylbiguanide)2Cl₂} chloride 
• 100126-54-3 6-amino-3-(4-chloro-phenyl)-4,4-dimethyl-3,4-dihydro-1H-[1,3,5]triazin-2-one 
• 88406-62-6 N-{[N'-(4-Chloro-phenyl)-guanidino]-imino-methyl}-2-[2-[N'-(4-chloro-phenyl)-guanidino]-5-oxo-3,5-dihydro-imidazol-(4Z)-ylidene]-acetamide 
• 110045-63-1 N-(4-chlorophenyl)-N'-<4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl>imidodicarbonimidic diamide 
• 96583-15-2 N-(4-chloro-phenyl)-6-(5-nitro-furan-2-yl)-[1,3,5]triazine-2,4-diamine 
• 51594-52-6 N¹-p-Chlor-phenyl-N⁵-acetoacetylbiguanid 
• 58247-24-8 1-(4-chlorophenyl)-3-amidinourea 
• 1482-62-8 1-(4-chlorophenyl)-3-cyanoguanidine 
• 30805-24-4 1-(4-chloro-phenyl)-6-methyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine 

Relevant academic research and scientific papers

NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE

Methods of treating diseases related to cGAS activation. Small molecule inhibitors of cGAS and pharmaceutical compositions and uses thereof in treating autoimmune diseases or inflammation.

Synthesis and in Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust in Vivo Antihyperglycemic Action

This work describes the design, synthesis in one step, and the in vitro, in vivo, and in silico antidiabetic evaluation of a series of ten alicyclic and aromatic (alkyl +aryl: alkaryl)biguanides, analogues of metformin and phenformin. The design was conceived using isosteric replacement, chain-ring transformation, and lower and higher homologation strategies. All compounds were obtained as crystals and their structure was confirmed on the basis of their spectral data (NMR and mass spectra), and their purity was ascertained by microanalysis. Compounds were in vitro evaluated as activators of AMP-Activated Protein Kinase (AMPK). The results indicated that compounds 4, 5, and 6 showed similar or even better effect compared to metformin. Docking analysis was performed with regulatory subunit γ of AMPK, showing several interactions with nucleotide binding pocket. The in vivo evaluation of compounds 4-6 at a single dose of 50 mg/kg was performed in a murine experimental model of diabetes. The results showed an important and robust decrease of plasmatic glucose levels (-40%). Compound 6 was selected for an oral glucose tolerance test, showing an antihyperglycemic effect similar to metformin. The in vivo results indicated that compounds 4-6 may be effective in treating experimental T2DM.

Novel compounds having treatment of immune diseases and use therof

The present invention relates to a novel compound capable of effectively treating and preventing immune disease and to a use thereof. The novel compound of the present invention suppresses the production of inflammatory cytokines and increases activities of regulatory T cells having immune regulatory ability. In addition, the compound of the present invention controls over an excessive immune response by inhibiting the production of autoantibodies and differentiation of osteoclasts, thereby being able to be used for treating immune diseases induced by regulatory anomalies of various immune response such as autoimmune disease, inflammatory diseases, and transplant rejection.(a) Cell toxicity effect control(MTT assay)(AA) Normal mouse cell(b) Autoantibody production immune reaction control(c) Inflammatory cytokine production control(d) Inflammatory gene expression controlCOPYRIGHT KIPO 2016